Definium Therapeutics, Inc. (DFTX) Cash Flow Statement
Definium Therapeutics, Inc. (DFTX) generated -$168.0M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$168.0M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DFTXDefinium Therapeutics, Inc.Follow DFTX — free
—
Price chart with a free account
- Market cap
- 4.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.05 | -0.05 | -0.06 | -0.08 | -0.13 | -0.17 | |
| Capital expenditure | — | — | — | 0.00 | 0.00 | -0.00 | |
| Free cash flow | — | — | — | -0.08 | -0.13 | -0.17 |
USD billions · SEC XBRL
Definium Therapeutics, Inc. — questions
- What is Definium Therapeutics, Inc.'s operating cash flow?
- -$168.0M over the twelve months to 2026-06-30.
- How much does Definium Therapeutics, Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Definium Therapeutics, Inc.'s free cash flow?
- -$168.0M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Definium Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.